OTCMKTS:BIOVF Swedish Orphan Biovitrum Q3 2025 Earnings Results & Report $45.72 0.00 (0.00%) As of 11/6/2026 Swedish Orphan Biovitrum beat analyst expectations on both earnings and revenue in its Q3 2025 results, released October 20, 2025. The company reported EPS of $0.64 versus the $0.4925 consensus estimate, while revenue of $826.53 million topped the $818.86 million estimate by $7.67 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateOctober 20, 2025TimeBefore Market Opens Swedish Orphan Biovitrum EPS ResultsActual EPS$0.64Consensus EPS $0.4925Beat/MissBeat by +$0.1475One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersSwedish Orphan Biovitrum Revenue ResultsActual Revenue$826.53 millionExpected Revenue$818.86 millionBeat/MissBeat by +$7.67 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Swedish Orphan Biovitrum Q3 2025 Earnings FAQ Did Swedish Orphan Biovitrum beat earnings estimates for Q3 2025? Swedish Orphan Biovitrum (OTCMKTS:BIOVF) reported earnings of $0.64 per share for Q3 2025, beating the consensus estimate of $0.4925. The report was announced on Monday, October 20, 2025. What was Swedish Orphan Biovitrum's revenue for Q3 2025? Swedish Orphan Biovitrum reported revenue of $826.53 million for Q3 2025, against a consensus estimate of $818.86 million. Swedish Orphan Biovitrum Earnings HeadlinesSwedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Rated "Moderate Buy" by Sell-Side AnalystsNovember 5 at 2:58 AM | americanbankingnews.comSwedish Orphan Biovitrum AB: Börje Ekholm is proposed as new Chair of the Sobi Board of DirectorsOctober 29, 2026 | finanznachrichten.deFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 8 at 1:00 AM | Weiss Ratings (Ad)Börje Ekholm is proposed as new Chair of the Sobi Board of DirectorsOctober 29, 2026 | marketscreener.comMSwedish Orphan Biovitrum Swings To Profit In Q3; Updates FY26 View; Stock Up 2.9%October 28, 2026 | rttnews.comHarry Gillis Raises Swedish Orphan Biovitrum Price Target to SEK570, Reiterates Buy on Tryngolza-Led Growth UpsideOctober 20, 2026 | tipranks.comSee More Swedish Orphan Biovitrum Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum and other key companies, straight to your email. Email Address About Swedish Orphan BiovitrumSwedish Orphan Biovitrum (OTCMKTS:BIOVF) AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate. The company was formed in 2010 when Biovitrum acquired Swedish Orphan and adopted the Swedish Orphan Biovitrum name. Based in Sweden, Sobi serves patients through operations and partnerships across Europe, North America and other international markets.View Swedish Orphan Biovitrum ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?The Ugly Truth Behind SoundHound’s Q3 ResultsSandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
